Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial

• Published in: Diabetes technology & therapeutics Vol. 25; no. 11; p. 817
• Main Authors: Marak, Martin Chase, Calhoun, Peter, Damiano, Edward R, Russell, Steven J, Ruedy, Katrina J, Beck, Roy W
• Format: Journal Article
• Language: English
• Published: United States 01-11-2023
• Subjects: Bionics; Blood Glucose; Blood Glucose Self-Monitoring - methods; Diabetes Mellitus, Type 1 - drug therapy; Humans; Insulin - therapeutic use; Insulin, Regular, Human; Pancreas; Reproducibility of Results; Blood glucose; Accuracy; Dexcom; Continuous glucose monitors; Type 1 diabetes
• ISSN: 1557-8593
• DOI: 10.1089/dia.2023.0287

Continuous glucose monitors (CGMs) have transformed the way people with type 1 diabetes can self-monitor glucose levels. Past studies have evaluated the accuracy of CGMs in clinic-based studies, but few have analyzed their accuracy in real-world settings. The Insulin-Only Bionic Pancreas Trial provided the opportunity to assess real-world accuracy of the blinded Dexcom G6 Pro sensor over the first 48-60 h of wear using a blood glucose meter (BGM) as a comparator for 1073 CGM-BGM pairs across 53 participants. The mean absolute relative difference (MARD) was 11.0% over a median period of 50 h (range 47-79 h). The MARD was 13.6% in the first 12 h, 10.5% in hours 12-24, and 10.1% after the first 24 h. These results are comparable with accuracy shown previously with laboratory-based measurements and provide real-world evidence of Dexcom G6 Pro accuracy, which improved after the first 12 h and then remained stable thereafter. Clinical Trial Registry: clinicaltrials.gov; NCT04200313.